A clinical audit of high-cost and off-label drug use in dermatology

The Australasian Journal of Dermatology
Natalie OngH Peter Soyer

Abstract

The use of high-cost, off-label, unsubsidised drugs has become valuable in the management of dermatology patients with challenging conditions unresponsive to conventional therapy. Currently, there is no dedicated funding and a paucity of evidence for such drugs. The aim of this audit was to review outcomes and costs. A retrospective clinical audit of high-cost off-label dermatology drug applications to the High Cost Drug's Subcommittee was undertaken at a tertiary public hospital in Brisbane, Queensland, between 2002 and 2013. Of 28 applications, 25 were approved. The medications included thalidomide, mycophenolate mofetil, cyclosporin, infliximab, rituximab and adalimumab. Over 70% of patients responded to treatment. Individual annual costs for these medications ranged from $2068 to $36 984. Adverse effects resulted in drug withdrawal in five cases. Despite the absence of dedicated funding for high-cost drugs and a rigorous committee approval process, most applications were approved, of which >70% benefited from treatment. This audit provides useful clinical experience with off-label use of high-cost drugs in difficult dermatological conditions.

References

Jan 1, 1990·Journal of the American Academy of Dermatology·V C HoJ J Voorhees
Aug 22, 2000·The British Journal of Dermatology·C E GrattanM W Greaves
Sep 5, 2001·The British Journal of Dermatology·M Grundmann-KollmannT M Zollner
Sep 27, 2003·Journal of the American Academy of Dermatology·Paradi MirmiraniVera H Price
Nov 25, 2003·The British Journal of Dermatology·K E HarmanUNKNOWN British Association of Dermatologists
Oct 3, 2006·Journal of the American Academy of Dermatology·Gino A VenaUNKNOWN Neo-I-30 Study Group
Nov 23, 2006·The Medical Journal of Australia·Madlen GazarianTerence J Campbell
Apr 20, 2007·Journal of the American Academy of Dermatology·Emel Bulbul BaskanHayriye Saricaoglu
Dec 4, 2009·The Journal of Dermatological Treatment·Mary E SockolovOmid Zargari
Nov 26, 2010·Journal of the American Academy of Dermatology·Karrie T AmorAlan Menter
Sep 29, 2011·Dermatology : International Journal for Clinical and Investigative Dermatology·Tina P Andersen, Karsten Fogh
Oct 5, 2011·Pediatric Dermatology·Weston T WaxweilerDean S Morrell
Dec 19, 2012·Annals of Internal Medicine·Alexa B KimballGregor B E Jemec
Apr 12, 2013·The Australasian Journal of Dermatology·Jane LiChristopher Baker
Nov 30, 2013·The Journal of Dermatological Treatment·Leni GeorgePablo Fernandez-Peñas
Mar 20, 2014·The British Journal of Dermatology·B MoriartyD Creamer
May 3, 2014·Journal of Clinical and Experimental Dentistry·Irene Belenguer-GuallarAriadna Claramunt-Lozano
Jun 11, 2014·Journal of the Royal Society of Medicine·Alexandra Teagle, Rachel Hargest
Oct 8, 2014·Expert Opinion on Emerging Drugs·Sabine G PlötzJohannes Ring
Nov 13, 2014·Acta Dermato-venereologica·Forum PatelEmanual Maverakis
Feb 25, 2015·American Journal of Clinical Dermatology·Rosalind HughesBrian Kirby

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Dermatology
Inacio R FaverRokea el-Azhary
Nature Reviews. Clinical Oncology
Vincent T Devita
Ophthalmology
D J Kilmartin, A D Dick
© 2021 Meta ULC. All rights reserved